Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: NASDAQ GM
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharma

Pernix Therapeutics Holdings Inc

+ Add to Watchlist

PTX:US

10.7300 USD 0.1700 1.56%

As of 20:10:00 ET on 02/27/2015.

Snapshot for Pernix Therapeutics Holdings Inc (PTX)

Open: 10.8400 Day's Range: 10.7200 - 11.0000 Volume: 630,830
Previous Close: 10.9000 52wk Range: 3.4400 - 11.6800 1-Yr Rtn: +192.37%

Stock Chart for PTX

No chart data available.
  • PTX:US 10.7300
  • 1D
  • 1M
  • 1Y
10.9000
Interactive PTX Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for PTX

Current P/E Ratio (ttm) -
Estimated P/E(12/2015) 11.7140
Relative P/E vs. SPX -
Earnings Per Share (USD) (ttm) -0.7282
Est. EPS (USD) (12/2015) 0.9160
Est. PEG Ratio -
Market Cap (M USD) 410.87
Shares Outstanding (M) 38.29
30 Day Average Volume 506,348
Price/Book (mrq) 4.6083
Price/Sale (ttm) 3.3491
Dividend Indicated Gross Yield -%
Cash Dividend (USD) -
Dividend Ex-Date 09/08/2001
5 Year Dividend Growth -
Next Earnings Announcement 05/12/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for PTX

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for PTX

Pernix Therapeutics Holdings, Inc. manufactures pharmaceuticals. The Company acquires, develops and markets medications for the pediatric market including treatments for dermatitis, statin-induced ubiquinone deficiency, deficiencies in active cultures due to diet and antibiotics, and upper respiratory conditions.

Douglas Drysdale "Doug"Chairman/President/CEOSanjay S PatelChief Financial Officer
Terence S Novak "Terry"Chief Operating OfficerBrian T DorseySenior VP:Pharmaceutical Dev
More Company Profile & Key Executives for PTX

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil